Anticancer Mechanisms of Paroxetine: Targeting MET and ERBB3 in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains a major global health challenge, ranking as the third most common malignancy and the second leading cause of cancer-related mortality worldwide. Metastatic CRC is particularly difficult to treat, with limited efficacy from current chemotherapies and targeted agents, often complicated by resistance and high costs. Drug repositioning—the investigation of established compounds for new indications—offers a promising strategy to accelerate oncology drug development, leveraging existing clinical safety data to identify novel anticancer applications (paper). Within this context, recent attention has focused on selective serotonin reuptake inhibitors (SSRIs) such as paroxetine, traditionally used to manage psychiatric disorders. Emerging preclinical evidence hints at potential anticancer effects in various tumor types, yet the mechanisms underlying these observations have not been fully elucidated. This study addressed whether paroxetine can exert direct antitumor effects against CRC cells, and if so, through which molecular pathways.

Key Innovation from the Reference Study

The pivotal innovation of this research is the demonstration that paroxetine, a clinically approved SSRI, can directly suppress viability and tumorigenic behaviors in human CRC cell lines by inhibiting specific receptor tyrosine kinases—namely MET and ERBB3. Unlike prior work focused on serotonin transporter (SERT) inhibition, this study reveals a multi-target profile for paroxetine, extending its pharmacological repertoire to include kinase inhibition relevant to cancer cell survival and proliferation (paper). Moreover, the investigation connects paroxetine’s kinase activity to downstream suppression of key oncogenic signaling pathways (AKT, ERK, and p38) and the induction of pro-apoptotic mechanisms (JNK and caspase-3 activation), providing a mechanistic rationale for its observed anticancer effects.

Methods and Experimental Design Insights

The study employed a combination of in vitro and in vivo approaches:

• Two well-characterized human CRC cell lines, HCT116 and HT-29, were used to assess cell viability, colony formation, and 3D spheroid growth following paroxetine treatment.
• Apoptosis was quantified using established markers (caspase-3 activation) and morphological analysis.
• Western blot and kinase assays interrogated the status of MET and ERBB3 phosphorylation, as well as downstream signaling intermediates (AKT, ERK, p38, JNK).
• In vivo validation was performed in athymic nude mice xenografted with HT-29 cells, with tumor volume monitored following systemic paroxetine administration.

This multi-layered design ensured that observed effects were consistent across both cellular and whole-animal systems, and that the implicated molecular mechanisms were directly tested.

Protocol Parameters

• cell viability assay | 7–26 μM paroxetine | HCT116, HT-29 | IC50 range for cytotoxicity determination | paper
• apoptosis induction assay | 10–30 μM paroxetine | HCT116, HT-29 | Dose-dependent increase in caspase-3 activity | paper
• colony formation assay | 10–30 μM paroxetine | HCT116, HT-29 | Inhibition of colony outgrowth | paper
• 3D spheroid assay | 15–30 μM paroxetine | HCT116, HT-29 | Suppression of spheroid formation | paper
• in vivo xenograft dosing | Not numerically specified | HT-29 nude mouse model | Evaluated tumor growth inhibition | paper
• Western blot/kinase inhibition | 10–30 μM paroxetine | HCT116, HT-29 | MET and ERBB3 phosphorylation status | paper
• workflow recommendation | 20–40 μM screening range | CRC and related cell models | Empirical optimization for new cell lines | workflow_recommendation

Core Findings and Why They Matter

Paroxetine treatment produced several convergent anticancer effects in vitro:

• Significant reduction in cell viability in both HCT116 and HT-29 CRC cell lines, with IC50 values ranging from 7 to 26 μM (paper).
• Induction of apoptosis, evidenced by increased caspase-3 activation and characteristic morphological changes.
• Suppression of colony formation and 3D spheroid growth, indicating blockade of tumorigenic potential.
• Inhibition of MET and ERBB3 phosphorylation, correlating with reduced activation of AKT, ERK, and p38, and increased activation of JNK and caspase-3 pathways.

In vivo, paroxetine administration significantly suppressed tumor growth in the HT-29 xenograft mouse model, supporting translational relevance (paper). The mechanistic link between paroxetine’s kinase inhibition—specifically as a MET and ERBB3 kinase inhibitor—and its pro-apoptotic, anti-proliferative effects represents a meaningful advance. These kinases are established drivers of oncogenic signaling and resistance in CRC, and their inhibition is a validated strategy for overcoming refractory disease.

Comparison with Existing Internal Articles

Recent internal resources have contextualized paroxetine’s emerging role in oncology. For instance, "Paroxetine Mesylate: Optimizing Oncology Protocols with SSRI Precision" (internal) highlights the compound’s dual function as a selective serotonin reuptake inhibitor and multi-kinase modulator, aligning with the reference study’s mechanistic findings. Similarly, "Molecular Mechanisms of Paroxetine: Beyond SSRI Activity" (internal) systematically reviews paroxetine’s activity against cytochrome P450 enzymes (notably CYP2D6, classifying it as a cytochrome P450 inhibitor), GRK2, and receptor tyrosine kinases, providing a broader pharmacological context for its anti-colorectal cancer activity. Whereas these reviews synthesize multi-domain data streams, the reference study uniquely validates MET and ERBB3 as principal anticancer targets in CRC models, thereby bridging prior mechanistic speculation with direct experimental evidence.

Limitations and Transferability

Despite its strengths, the study’s conclusions are subject to several limitations. Most notably, the work is preclinical: while promising, in vitro and xenograft data do not fully predict efficacy or safety in human CRC patients. Precise pharmacokinetics and achievable tumor concentrations in clinical settings remain uncharacterized. Additionally, the spectrum of paroxetine’s kinase inhibition (including potential off-target effects on other kinases such as KIT or JAK) was not comprehensively profiled in this study (internal). Transferability to other cancer types, or to combination regimens with existing chemotherapeutics, would require further investigation. Finally, the risk/benefit profile for repurposing a psychiatric medication in oncology would need systematic assessment in future translational and clinical research.

Why this cross-domain matters, maturity, and limitations

Paroxetine’s repositioning from psychiatry to oncology exemplifies the value of multi-target compounds in translational research. Leveraging its established clinical safety, researchers can more rapidly test anticancer hypotheses in preclinical models. However, cross-domain translation is not without risk: the pharmacodynamic requirements for CNS and oncology indications may differ significantly, and optimal dosing or toxicity thresholds may not align (paper). As such, while this approach accelerates early-stage discovery, it requires rigorous clinical validation before adoption in standard care.

Research Support Resources

To facilitate similar workflows in kinase and oncology research, investigators may employ Paroxetine Mesylate (SKU C8698), available from APExBIO, which is characterized as a selective serotonin reuptake inhibitor with verified MET and ERBB3 kinase inhibitory activity. This reagent aligns with literature-backed concentrations used in the cited study and supports reproducible protocol development in both cellular and animal models. See product documentation for storage and handling guidelines to maintain compound stability (source: product_spec).